These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23617953)

  • 21. Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
    Rinne UK
    Eur Neurol; 1987; 27 Suppl 1():120-5. PubMed ID: 3428305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
    Pacchetti C; Martignoni E; Sibilla L; Bruggi P; Turla M; Nappi G
    Eur Neurol; 1990; 30(6):319-23. PubMed ID: 2289507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
    Nordera GP; Lorizio A; Lion P; Durisotti C; D'Andrea G; Ferro-Milone F
    Eur Neurol; 1987; 27 Suppl 1():76-80. PubMed ID: 3322839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane.
    Taylor PW; Keenan MH
    Curr Med Res Opin; 2006 Mar; 22(3):603-15. PubMed ID: 16574043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group.
    Clin Neuropharmacol; 1989 Dec; 12(6):498-505. PubMed ID: 2691069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS; Covicković-Sternić N
    Neurologija; 1990; 39(2):99-105. PubMed ID: 2267052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia.
    Bayer AJ; Day JJ; Finucane P; Pathy MS
    J Clin Pharm Ther; 1988 Jun; 13(3):191-4. PubMed ID: 3209626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
    Chouza C; Romero S; de Medina O; Aljanati R; Scarmelli A; Caamano JL; Gonzales Panizza V
    Eur Neurol; 1987; 27 Suppl 1():59-67. PubMed ID: 3428309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
    Fischer PA; Baas H
    Eur Neurol; 1987; 27 Suppl 1():81-7. PubMed ID: 3322840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
    Caraceni TA; Celano I; Parati E; Girotti F
    J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1142-6. PubMed ID: 591982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
    MacMahon DG; Sachdev D; Boddie HG; Ellis CJ; Kendal BR; Blackburn NA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):220-3. PubMed ID: 2182781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
    Rondot P; Ziegler M; Aymard N; Holzer J
    Eur Neurol; 1987; 27 Suppl 1():114-9. PubMed ID: 3322835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide.
    Qu Y; Lai WL; Xin YR; Zhu FQ; Zhu Y; Wang L; Ding YP; Xu Y; Liu HF
    AAPS PharmSciTech; 2019 Sep; 20(8):312. PubMed ID: 31529266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers.
    Nyholm D; Lewander T; Gomes-Trolin C; Bäckström T; Panagiotidis G; Ehrnebo M; Nyström C; Aquilonius SM
    Clin Neuropharmacol; 2012; 35(3):111-7. PubMed ID: 22549097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa pharmacodynamics.
    Fullerton T
    Neurology; 1994 Feb; 44(2):365-6. PubMed ID: 8309598
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.
    Walker AD; Adachi JD
    Curr Med Res Opin; 2011 Sep; 27(9):1749-54. PubMed ID: 21781014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
    Jorga K; Fotteler B; Schmitt M; Nielsen T; Zürcher G; Aitken J
    Eur Neurol; 1997; 38(1):59-67. PubMed ID: 9252801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
    Poewe WH; Lees AJ; Stern GM
    Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
    Lees AJ
    Eur Neurol; 1987; 27 Suppl 1():126-34. PubMed ID: 3428306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.